Gilead Sciences · Multi-Quarter Financial Trends

16 quarters · As reported by the company · Amounts in USD billions← GILD

Quarter	Period End	Revenue ($B)	YoY	Gross Margin	Operating Income ($B)	Net Income ($B)	Net Margin	Free Cash Flow ($B)	EPS	Buybacks ($B)	Dividends ($B)
FY2026 Q2	2026-06-30	7.80	+10.2%	79.8%	-10.39	-10.50	-134.5%	3.43	-8.45	0.36	1.03
FY2026 Q1	2026-03-31	6.96	+4.4%	79.2%	2.59	2.02	29.0%	2.43	1.61	0.42	1.04
FY2025 Q4	2025-12-31	7.93	+4.7%	79.5%	1.98	2.18	27.5%	3.12	1.75	0.23	0.99
FY2025 Q3	2025-09-30	7.77	+3.0%	79.8%	3.33	3.05	39.3%	3.96	2.43	0.44	1.01
FY2025 Q2	2025-06-30	7.08	+1.8%	78.8%	2.47	1.96	27.7%	0.72	1.56	0.53	0.99
FY2025 Q1	2025-03-31	6.67	−0.3%	76.9%	2.24	1.32	19.7%	1.65	1.04	0.73	1.01
FY2024 Q4	2024-12-31	7.57	+6.4%	79.1%	2.45	1.78	23.6%	2.83	1.43	0.35	0.97
FY2024 Q3	2024-09-30	7.55	+7.0%	79.1%	0.89	1.25	16.6%	4.17	1.00	0.30	0.98
FY2024 Q2	2024-06-30	6.95	+5.4%	77.8%	2.64	1.61	23.2%	1.20	1.29	0.10	0.97
FY2024 Q1	2024-03-31	6.69	+5.3%	76.8%	-4.32	-4.17	-62.4%	2.11	-3.34	0.40	0.99
FY2023 Q4	2023-12-31	7.11	−3.7%	70.6%	1.61	1.43	20.1%	1.95	1.14	0.15	0.94
FY2023 Q3	2023-09-30	7.05	+0.1%	77.8%	2.62	2.18	30.9%	1.63	1.73	0.30	0.95
FY2023 Q2	2023-06-30	6.60	—	78.1%	1.67	1.05	15.8%	2.20	0.83	0.15	0.94
FY2023 Q1	2023-03-31	6.35	—	77.9%	1.71	1.01	15.9%	1.64	0.80	0.40	0.97
FY2022 Q4	2022-12-31	7.39	—	81.1%	2.27	1.64	22.2%	2.39	1.29	0.79	0.92
FY2022 Q3	2022-09-30	7.04	—	80.2%	2.84	1.79	25.4%	2.71	1.42	0.18	0.93

Quarterly figures come from the company's 10-Q and 10-K filings. The fourth quarter is derived as the full year minus the first three quarters; cash flow items are converted from fiscal year-to-date totals into single quarters.